BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant n… Read more
BridgeBio Oncology Therapeutics, Inc. (BBOT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.103x
Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) has a cash flow conversion efficiency ratio of -0.103x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.23 Million) by net assets ($411.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BridgeBio Oncology Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BridgeBio Oncology Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BridgeBio Oncology Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Awakn Life Sciences Corp
PINK:AWKNF
|
0.391x |
|
Scinai Immunotherapeutics Ltd
NASDAQ:SCNI
|
-0.164x |
|
GREEN SHIFT COMMODITIES
F:7WV
|
N/A |
|
POSCO
KQ:005490
|
N/A |
|
Skyline Investment S.A.
WAR:SKL
|
-0.004x |
|
Simble Solutions Ltd
AU:SIS
|
1.447x |
|
Lenox Pasifik Investama Tbk PT
JK:LPPS
|
0.000x |
|
Mondo TV S.p.A
F:MJE
|
-0.167x |
Annual Cash Flow Conversion Efficiency for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $411.10 Million | $-113.89 Million | -0.277x | -6745.05% |
| 2024-12-31 | $188.72 Million | $-763.82K | -0.004x | -100.00% |
| 2023-12-31 | $-63.57K | $-52.08 Million | 819.252x | -- |